Vivalto Partners announces the acquisition of Linnea

Vivalto Partners announces the 100% acquisition of Linnea, a leading international pharmaceutical manufacturer of botanical ingredients in Switzerland. This transaction marks a significant milestone for Vivalto Partners and represents a primary buyout, with a substantial investment from Linnea's management team to support the company's continued growth and innovation in the fast-expanding field of plant-based therapeutics and botanical ingredients.

Lenz & Staehelin assisted Vivalto Partners on Swiss tax matters in the context of the acquisition of Linnea SA.